


Keywords:

Introduction

1-3 .

Methodology

B
4



Discussion



Conclusion



References

1. Wen S, Dai L, Wang L (2019) Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. *Oncologist* 24: 1070-1081.
2. Li T, Zhang F, Wu Z (2020) PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors. *Lung Cancer* 139: 146-150.
3. Liu S, Huang T, Liu M (2020) The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients. *Front Oncol* 10: 726.
4. Wu X, Zhou H, He Z (2020) Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report. *Transl Lung Cancer Res* 9: 2494-2499.
5. Wang R, Qin J, Fan Y (2020) Responses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCAL1- ALK Fusion Variant: A Case Report. *Onco Targets Ther* 13: 4183-4187.
6. Wu X, Wang W, Zou B (2020) Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report. *Thorac Cancer* 11: 1695-1698.
7. Jin L, Wang Y, Li S (2020) . *Lung Cancer* 146: 382-384.
8. Zhang J, Zou C, Zhou C (2020) A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib. *J Thorac Oncol* 15: 1073-1077.
9. Ma L, Zhang Q, Dong Y (2020) SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer. *Lung Cancer* 143: 97-100.
10. Cai C, Long Y, Li Y (2020) Coexisting of COX7A2L-ALK, LINC01210-ALK, ATP13A4-ALK and Acquired SLCO2A1-ALK in a Lung Adenocarcinoma with Rearrangements Loss During the Treatment of Crizotinib and Ceritinib: A Case Report. *Onco Targets Ther* 13: 8313-8316.